Medtronic Stock Is Sliding Because Its Hypertension Treatment Trial Didn’t End Early
This transcript is for your personal, non-commercial usage only. To bid presentation-ready copies for organisation to your colleagues, clients oregon customers sojourn http://www.djreprints.com.
https://www.barrons.com/articles/medtronic-stock-hypertension-treatment-study-51634578280
Updated Oct. 18, 2021 2:29 p.m. ET / Original Oct. 18, 2021 1:44 p.m. ET
- Order Reprints
- Print Article
Medtronic was falling Monday aft the aesculapian instrumentality shaper said a objective survey of its renal-denervation strategy wasn’t stopped aboriginal arsenic expected by analysts who thought the result would beryllium much positive.
The banal was down 5.3% to $120.93.
Medtronic (ticker: MDT) said precocious Friday successful a regulatory filing that a objective proceedings of its Symplicity renal-denervation...
What's Your Reaction?
